• In recent months, Driehaus Capital Management and Deerfield Management Company have sharply increased their holdings in Praxis Precision Medicines, adding hundreds of thousands of shares and committing a combined investment of more than US$346.79 million as the company filed two FDA new drug applications for ulixacaltamide and relutrigine.
• This combination of larger institutional ownership, advancing late‑stage neuroscience candidates and a cash position supported by roughly US$1.55 billion in funding is drawing attention to Praxis’s transition toward a potential commercial model.
• We’ll now examine how this influx of institutional capital and FDA filings could reshape Praxis Precision Medicines’ existing investment narrative.

Invest in the nuclear renaissance through our list of 87 elite nuclear energy infrastructure plays powering the global AI revolution.

Praxis Precision Medicines Investment Narrative Recap

To own Praxis Precision Medicines, you have to believe its late stage CNS portfolio can convert promising trial data and FDA filings into approved, commercially viable therapies before the cash runs down. In the near term, the key catalyst is regulatory progress on ulixacaltamide and relutrigine, while the biggest risk is that pivotal epilepsy trials underperform earlier data. The recent institutional buying and NDAs support the story but do not remove that core clinical risk.

The most relevant recent development here is Praxis’s dual FDA new drug applications for ulixacaltamide in essential tremor and relutrigine in rare developmental epilepsies. These filings, combined with a cash position supported by roughly US$1.55 billion of funding, give the company room to push its pivotal epilepsy programs forward, reinforcing the existing catalysts around vormatrigine’s Phase 3 readouts while keeping financing risk somewhat contained in the near term.

Yet even with strong funding and fresh institutional interest, investors should be aware that clinical setbacks in the pivotal epilepsy trials could still...

Praxis Precision Medicines’ narrative projects $724.1 million revenue and $89.5 million earnings by 2029. This requires 359.5% yearly revenue growth and an earnings increase of about $362.5 million from -$273.0 million today.

Uncover how Praxis Precision Medicines' forecasts yield a $449.13 fair value, a 53% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were already projecting Praxis could reach about US$2.1 billion in revenue and roughly US$783.6 million in earnings by 2029, so this new wave of NDAs and late stage progress may either reinforce that bullish view or prompt a rethink of how quickly those targets might be reached.

Explore 4 other fair value estimates on Praxis Precision Medicines - why the stock might be a potential multi-bagger!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Praxis Precision Medicines research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Praxis Precision Medicines research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Praxis Precision Medicines' overall financial health at a glance.

Searching For A Fresh Perspective?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• Find 48 companies with promising cash flow potential yet trading below their fair value.
• We've uncovered the 14 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 30 best rare earth metal stocks of the very few that mine this essential strategic resource.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.